After the markets closed on Monday, HealthStream reported solid first quarter 2014 results. More specific, sales rose 29% year-over-year, to $38.3 million, nearly spot on the consensus target of $38.5 million; adjusted EBITDA—the key profit metric we monitor—were $6.1 million, modestly above the $5.8 million Street estimate; and GAAP EPSRead More
Post Tagged with: "healthcare"
Express Scripts Department of Defense Tricare Contract Renewal Should Help to Further Improve Investor Sentiment
Friday evening Express Scripts announced that the Department of Defense had renewed its Tricare pharmacy contract with the company for another seven years (from May 2015 through April 2022). We do not believe this news will come as a surprise to investors, as the contract was broadly expected to beRead More
Sarepta Therapeutics Updated FDA Guidance Suggests Flexibility, Open-Label Trial for Pivotal, AA Filing in 2014
Sarepta Therapeutics announced plans to submit a new drug application (NDA) to the FDA by the end of 2014 for its lead exon-skipping drug eteplirsen for the treatment of Duchenne muscular dystrophy (DMD) and, more importantly, announced updated guidance that allows for an open-label confirmatory Phase III trial outside theRead More